Responses
Regular and young investigator award abstracts
Immune-stimulants and immune modulators
576 NL-201, a de novo IL-2 and IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies
Compose a Response to This Article
Other responses
No responses have been published for this article.